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A B S T R A C T 
The synthesis of a new hexacyclic system was realized starting from tryptamines and exploiting as 
a key step a sequential Pd-catalyzed N-arylation/acylation reaction. Having topoisomerases as 
biological target and the campthotecins class as benchmark, the new scaffold was decorated with 
substituents having different polarity and tested as Topoisomerase I inhibitors. 
© 2013 xxxxxxxx. Hosting by Elsevier B.V. All rights reserved.   
 
 
1. Introduction 
The topoisomerases are ubiquitous enzymes essential for the vital cellular 
processes as involved in different steps of DNA replication, transcription, 
recombination and several reviews describe their characteristics and their 
activity on DNA in cells[1,2,3,4]. In particular topoisomerase I and 
topoisomerase II play a key role binding to the DNA double helix 
inducing temporary single (Topo I) or double strand break (Topo II) 
allowing relaxation of the DNA for replication. Then the inhibition of 
these enzymes is lethal and leads to cell death, thus establishing Topo I 
and II as promising targets for cancer treatment and as a goal for the 
development of a new class of anticancer drugs.  
Recently we realized a new series of bis-heteroarylmaleimides and bis-
heterofused imides endowed with antiproliferative effects on human 
tumor cells (NCI-H460 lung carcinoma) and rat aortic smooth muscle 
cells (SMC's), due to the ability to stabilize the DNA-intercalator-
topoisomerase II ternary complex[5,6]. 
While many cytotoxic drugs used in the clinical practice act on Topo II, 
only camptothecins have been developed as inhibitors of Topo I. 
Camptothecin (CPT) (Fig. 1), a natural alkaloid first isolated from extracts 
of Camptotheca acuminata, selectively poisons Topo I and exhibits strong 
antineoplastic activity against colorectal, breast, lung and ovarian 
cancers[7]. Topotecan (TPT) and Irinotecan (Fig. 1), are the most potent 
synthetic derivatives of CPT in clinical use. However, several limitations 
of CPT and its analogs such as solubility, toxicity, resistance and above 
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all the instability under physiological conditions have encouraged the 
development of new CPT analogues and non-CPT topo I inhibitors. The 
interest in topoisomerase I as a therapeutic target promoted various efforts 
to identify other chemotypes effective as topoisomerase inhibitors and 
chemical/modelling efforts to rationally design specific analogs among 
known inhibitors[8,9,10,11]. During the last years several tetra- and 
pentacyclic structures containing the indoline fragment has received much 
attention due to the structural correlation with natural compounds 
belonging to the alkaloids class endowed with biological activity as 
cyclooxygenase/5-lipooxygenase inhibitors, characterized by the presence 
of the pyrrolo[3,2-de]acridine subunit[12],  indolocarbazoles non-CPT topo 
I inhibitors[13,14,15,16] and analogues of physostigmine alkaloids[17,18,19,20].  
 
 
 
Fig. 1. Topo I inhibitor compounds 
 
Having topoisomerase I as biological target, our efforts were addressed to 
realize new heteropolycyclic structure based on scaffold hopping 
combining some of the structural features of 5-lipooxygenase inhibitors,  
physostigmine derivatives and CPT derivatives. (Scheme 1) 
 
 
 
Scheme 1. Scaffold design 
2. Result and discussion 
Two possible retrosynthetic pathways were initially identified to obtain 
the scaffold: path A, starting from triptamine and path B starting from 3-
substituted indoline, in both cases followed as a key steps by a sequence 
of N-arylation/aromatic acylation. The minor steps prompted us to follow 
path A. (Scheme 2, path A). 
 
 
 
 
Scheme 2. Selected strategies for the synthesis of the scaffold 
 
Starting from substituted tryptamines 1, the first step provided the 
formation of the tricyclic tetrahydropyrrolo[2,3-b]indoles 3 through the 
intramolecular reaction of the carbamates 2 under the catalysis of Pd-
complex/Lewis acid (Pd(PPh3)4/Et3B) in THF as solvent at r.t.. The 
alkylative amination step was performed in the presence of allyl alcohol 
as electrophile resulting the contemporary insertion of the allyl substituent 
in position 3a[21]. Both Pd-complex and Et3B Lewis acid were necessary to 
obtain allylation. The intramolecular amination was stereoselective giving 
only the cis isomer in the junction of the B and C rings, as stated by 1H 
NMR NOESY experiments (see supp. Inf.) (Scheme 3)[22]. The tricyclic 
systems 3 were in all the cases obtained as enantiomers mixture. Attempts 
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to separate the isomers as diastereoisomers by using chiral carbamate 
derivatives of the triptamine ((S)-(-)-2-methylbutyl carbamate, (1S)-(+)-
menthyl carbamate, (1R)-(-)-myrtenol carbamate) gave unsatisfactory 
results or failed in the cyclization step.   
 
 
 
Scheme 3. Reagents and conditions: (i) ClCO2Me (1.2 eq), Et3N (1.2 eq), MeOH, 0 °C, 10 min, rt, 24 h, 90-95 %; (ii) Pd(PPh3)4  (0.5 mol%), allyl alcohol 
(1.2 eq), Et3B  (1.2 eq), THF, 0 °C, 30 min, rt, 24 h,  77-91%. 
 
The following key step consisted in the Pd-catalyzed N-arylation of the 
derivatives 3 with 2-chloroquinoline-3-carbaldehydes 4, affording the 
products 5. (Scheme 4)  The reaction conditions were optimized as 
showed in Table 1, the best conditions used the Pd2(dba)3 as catalyst and 
triisobutylphosphatrane (IAPU) as ligand, in toluene at 110 °C, in the 
presence of t-BuONa as base. The reaction required the protection of the 
formyl substituent as acetal. (Table 1, entry 8)  
 No result was obtained attempting the SNAr reaction.
 
 
 
Scheme 4. Reagents and conditions: (i) Pd2(dba)3 (2 mol%), triisobutylphosphatrane (8 mol%), t-BuONa (1.4 eq), toluene, 110 °C, 5h, 87-92%.  
Table 1 – Optimization of Pd-catalyzed N-arylation reaction 
Entry Catalyst Ligand Base T °C Time (h) Yield (%) 
1 Pd(OAc)2 (2 mol%) BINAP (2 mol%) Cs2CO3 (5eq) 110 24 10 
2 Pd(OAc)2 (2 mol%) DPPF (2 mol%) t-BuOK (1.4 eq) 110 24 5 
3 Pd(OAc)2 (2 mol%) triisobutylphosphatrane (4 mol%) Cs2CO3 (5eq) 110 24 25 
4 Pd2(dba)3 (5 mol%) BINAP (10 mol%) t-BuONa (1.4 eq) 110 24 60 
5 Pd2(dba)3 (5 mol%) BINAP (10 mol%) Cs2CO3 (2eq) 100 24 70 
6 Pd2(dba)3 (1 mol%) triisobutylphosphatrane (4 mol%) t-BuONa (1.4 eq) 100 24 75 
7 Pd2(dba)3 (0.5 mol%) triisobutylphosphatrane (2 mol%) K2CO3 (5 eq) 100 24 75 
8 Pd2(dba)3 (2 mol%) triisobutylphosphatrane (8 mol%) t-BuONa (1.4 eq) 110 3 85 
 
 
The subsequent step was the intramolecular Friedel-Craft reaction of the 
intermediate 5 using the protected formyl group directly[23]. The 
polyheterocyclic alkylated derivative was obtained as a mixture of two 
products 6 and 7, one of which was the oxidized form of the alkylated 
product 6. (Scheme 5) The treatment of the mixture with oxidants MnO2 
and mCPBA resulted in the complete  transformation of compound 6 in 7. 
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Scheme 5. Reagents and conditions: (i) BF3-Et2O (3-5 eq), CH2Cl2, 0 °C, 10 min, rt, 48h; (ii) MnO2 (4 eq), m-CPBA (5 mol%), THF/H20 (4:1), 60 °C, 
12h, 50-80%. 
 
The insertion of different substituents on the polycyclic scaffold 7 has 
been realized with the aim to evaluate changes in the biological activity, 
in fact the presence of polar groups may have strong interaction with the 
enzyme. The functionalization in position 1 may be obtained from 7 by 
reduction of the carbomethoxy group to give compound 8 or by hydrolysis 
obtaining derivatives 9a-d. (Scheme 6) 
 
Scheme 6. Reagents and conditions: (i) Red-Al® (10 eq), toluene, 0 °C, 10 min, 110 °C, 5h, 50%; (ii) NaOH (15 eq), EtOH/H2O (3:1), 80 °C, 5-8h, 65-
85%; (iii) BBr3 (2.5 eq), CH2Cl2, 40 °C, 24-48h, 70-80%. 
 
The methoxy substituents may be present in positions 5 and 10, the 
reaction with BBr3 of the intermediates 9 resulted in the formation of the 
phenolic derivatives 10. The 2-hydroxyethyl substituent selected as polar 
branch, was formed in position 3a from the allyl susbstituent of the 
compound 7b, through the sequence oxidation-reduction affording the 
compounds 12 and 13. (Scheme 7) 
 
 
Scheme 7. Reagents and conditions: (i) OsO4 (4 mol%), NaIO4 (3 eq), lutidine (2 eq), THF/H2O (5:1), rt, 24h, 75%; (ii) NaBH4 (1.2 eq), MeOH, rt, 3h, 
65%; (iii) NaOH (15 eq), EtOH/H2O (3:1), 80 °C, 6h, 61%. 
 
The projected decoration of the scaffold involved the insertion of a 
dimethylaminomethyl group, present also on the TPT, synthetic derivative 
of CPT. The derivative was obtained through a Mannich reaction effective 
only on the phenolic derivatives 15a, b obtained by hydrolysis of the 
methylethers 9b and 13 and after protection of the nitrogen atom as Boc 
derivative. (Scheme 8) 
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Scheme 8. Reagents and conditions: (i)  BBr3 (2.5 eq), CH2Cl2, 40 °C, 12-48h, 50-70%.; (ii)  Boc2O (3 eq), Et3N (2-4 eq), EtOH, rt, 48h; (iii) Piperidine (3 
eq), EtOH, 80 °C, 1-2h, 60-80 %; (iv) CH2O (4 eq), Me2NH (3 eq), EtOH, rt, 24-48h, 56-60%; (v) TMSCl (5 eq), MeOH, rt, 6h, 78%. 
 
The Figure 2 and Table 2 showed as convenience the sum of the different 
substituents on compounds 7-17 evaluated for their antiproliferative 
activity.  
 
Fig. 2. Different substituents on the hexacyclic scaffold 
Table 2 – Different substituents on the scaffold 
Compd. R1 R2 R3 R4 R5 
7b CO2Me Allyl H OMe H 
8 Me Allyl OMe OMe H 
9a H Allyl H H H 
9b H Allyl H OMe H 
9c H Allyl OMe H H 
9d H Allyl OMe OMe H 
10b H Allyl H OH H 
10d H Allyl OH OH H 
13 H (CH2)2OH H OMe H 
15a Boc Allyl H OH H 
15b Boc (CH2)2OH H OH H 
16a Boc Allyl H OH CH2NMe2 
16b Boc (CH2)2OH H OH CH2NMe2 
17 H llyl H OH CH2NMe2 
 
 
3. Biological evaluation 
3.1. Antiproliferative activity. The ability of new derivatives to inhibit 
cell growth was investigated by an in vitro assay on three human tumor 
cell lines, H460 (large cell lung carcinoma), MSTO-211H (human 
biphasic mesothelioma) and HeLa (cervix adenocarcinoma). The results, 
expressed as GI50 values, i.e. the concentration (µM) of compound that 
induces 50% cell death with respect to the control culture, are shown in 
Table 3. The CPT was used as reference compound. 
The results indicate for all test derivatives a detectable antiproliferative 
activity, with GI50 values in the micromolar range. Inside the new class of 
hexacyclic compounds, the most active is 13, characterized by the 2-
hydroxyethyl substituent in R2 and a methoxy group in R4, which shows 
GI50 values in the low micromolar range in all cell lines taken into 
consideration. For 9b and 10d, GI50 values lower that 10 µM are obtained 
in two cell lines (H460 and MSTO-211H), while for all other compounds 
the cytotoxicity is lower and indeed GI50 values ranging from 13.0 to 35.2 
µM can be observed. 
On the basis of these data, some preliminary structure-activity 
relationships could be drawn. In particular, the presence of the 2-
hydroxyethyl chain in 13 seems to be determinant for the biological 
activity. Indeed, its replacement with the allyl substituent (9b) induces a 
significant decrease in cytotoxicity, especially in H460 and HeLa cells 
where an increase of about of one order of magnitude can be observed. 
This drop in antiproliferative ability is confirmed for all compounds 
carrying the allyl moiety in R2 (8, 9a-d, 10b, 10d, 15a, 16a and 17) apart 
from the different groups inserted in the others position of the hexacyclic 
scaffold. Nevertheless, the effectiveness of the 2-hydroxyethyl is 
considerably dampened by the insertion of BOC in R1 and hydroxyl in R4 
and/or a dimethylaminomethyl side chain in R5 as suggested by the 
comparison between 13 and 15b or 16b. It is noteworthy that the presence 
of BOC appears detrimental for the occurrence of the cytotoxic capacity 
in all compounds (15a, 15b, 16a and 16b) and indeed they show high GI50 
values. 
 
 
Table 3 – Cell growth inhibition in the presence of test derivatives and CPT as reference compound. 
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Compd. GI50a (µM) 
 H-460 MSTO-211H HeLa 
8 › 50 34.2 ± 7.9 18.3 ± 1.2 
9a 14.4 ± 0.9 13.0 ± 2.1 16.5 ± 1.0 
9b 8.9 ± 1.4 7.8 ± 1.0 14.8 ± 1.5 
9c 32.2 ± 4.7 14.4 ± 3.3 30.7 ± 4.8 
9d 18.6 ± 0.3 13.5 ± 2.6 16.6 ± 3.8 
10b › 50 18.7 ± 0.6 19.0 ± 0.5 
10d 4.8 ± 1.0 7.0 ± 0.9 15.3 ± 0.8 
13 0.85 ± 0.09 1.9 ± 0.3 1.4 ± 0.3 
15a 32.7 ± 0.8 24.1 ± 1.6 30.5 ± 1.8 
15b 26.8 ± 2.0 13.7 ± 0.9 13.0 ± 2.2 
16a 17.8 ± 1.7 22.8 ± 2.4 35.2 ± 1.6 
16b 16.4 ± 1.4 20.0 ± 1.6 13.0 ± 1.0 
17 26.2 ± 1.2 29.1 ± 1.9 29.3 ± 5.6 
CPT 0.0020 ± 0.0002 0.0021 ± 0.0001 0.0054 ± 0.0002 
 
a
 Mean values ±SD of at least three independent experiments are reported. 
 
3.2. Interaction with DNA. The interesting antiproliferative effect 
exerted by the most biologically active compound (13) and in particular, 
the presence of a wide planar heteropolycyclic scaffold, suggested an 
investigation on the ability to form a molecular complex with DNA 
through an intercalative mode of binding, in accordance with previous 
studies[24]. For this purpose flow linear dichroism (LD) experiments were 
performed with DNA solutions in the absence and in the presence of 13 
and the corresponding allyl derivative 9b. The obtained LD spectra are 
shown in Figure 3, the UV-vis absorbance spectra of the test compounds 
(A) are also reported as reference. 
 
Fig. 3. Absorbance spectra (A) for compounds 13 and 9b at 1.2 x 10-5M. Linear flow dichroism spectra (LD) for compounds 13 and 9b at different 
[compound]/[DNA] ratios: dotted line=0; continuous line=0.08. [DNA] = 1.9 x 10-3M. 
Both LD spectra show an evident negative signal at 260 nm, typical of the 
macromolecule and due to the strong absorption of DNA base pairs at this 
wavelength. Moreover, interestingly, in the presence of the considered 
derivative (continuous lines) a further dichroic signal appears at higher 
wavelengths (380-520 nm). Because no contribution from the 
macromolecule exists in this latter spectral region, the occurrence of the 
signal has to be attributed to the added chromophore, which, otherwise, 
absorbs at these wavelengths (see absorption spectra, A). Since small 
molecules, such as 13 and 9b, cannot become oriented in the flow field, 
the occurrence of the LD signal has to be attributed to the formation of a 
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molecular complex with DNA that permit them the orientation. Moreover, 
the negative sign of the LD signal, as the strong band at 260 nm, indicate 
a parallel orientation of the planar hexacyclic system of new derivatives 
with respect to the plane of the purine and pyrimidine base pairs. This 
means that 13 and 9b form a complex with DNA via an intercalative 
mode of binding. 
 
3.3. Effect on topoisomerase. DNA topoisomerase I has been shown to 
be the target of many anticancer agents, both camptothecin (topotecan and 
irinotecan) and non-camptothecin (indolocarbazoles and phenanthroline) 
derivatives[2,3]. From a mechanistic point of view, agents that inhibit 
topoisomerase I can be grouped into two classes: poisons and suppressors. 
Both inhibit the catalytic activity of the enzyme (supercoiled DNA 
relaxation), nevertheless poisons, like CPT, stabilize a covalent 
intermediate complex, called cleavable complex, thus producing single-
stranded DNA breakages. Otherwise, suppressors interfere with other 
steps of the catalytic cycle without stabilize the cleavable complex, for 
example through a direct interaction with the enzyme or the formation of a 
molecular complex with DNA[25,26].  
In this connection and based on the above results, we investigate the 
ability of the most active derivative 13 and of the structurally related 9b, 
to affect the catalytic activity of topoisomerase I. Figure 4 shows the 
effect of the test compounds on the relaxation of supercoiled DNA 
mediated by topoisomerase I. The enzyme removes supercoils from 
pBR322 plasmid DNA (lane DNA) giving rise to a population of relaxed 
DNA topoisomers that migrates differently depending on their linking 
number (lane topo I). The results shown in Figure 4 indicate that both 13 
and 9b affects the relaxation activity of the enzyme and indeed they 
induce both a decrease in the number of topoisomers and an increase in 
the intensity of the band corresponding to the relaxed plus nicked DNA. 
This behavior, similar to that observed for CPT, a well-known 
topoisomerase I poison, demonstrate the capacity of test compounds to 
interfere with the catalytic activity, but does not allow to establish if it is 
due to a poisoning effect. 
 
 
Fig. 4. Effect of compounds 13 and 9b on relaxation of supercoiled 
pBR322 DNA mediated by topoisomerase I. Supercoiled DNA (lane 
DNA) was incubated with topoisomerase I in the absence (lane topo I) 
and in the presence of test compounds at indicated concentration. 
CPT was used as reference. 
Therefore, to discriminate between a specific poisoning action and other 
possible nonspecific effects, due for example to DNA intercalation, the 
experiments were performed with agarose gel containing ethidium 
bromide and the results are showed in Figure 5, in comparison with CPT. 
Indeed, in these latter experimental conditions the DNA species moving 
toward the anode become progressively saturated by the intercalative 
effect of ethidium and this influences significantly their rate of migration. 
Otherwise, the electrophoretic mobility of the band corresponding to the 
nicked DNA, resulting from the stabilization of the cleavable complex, is 
unaffected by the presence of ethidium bromide and thus can be easily 
detected[27]. 
 
 
Fig. 5. Effect of compounds 13 and 9b on the stabilization of covalent-
DNA-topoisomerase I complex. Supercoiled DNA (lane DNA) was 
incubated with topoisomerase I in the absence (lane topo I), in the 
presence of test compounds at indicated concentration and in the 
presence of ethidium bromide in the gel and buffer. CPT was used as 
reference 
 
The results obtained by incubating DNA and enzyme in the presence of 
increasing concentrations (from 10 to 100 µM) of 13 indicate for this 
compound the ability to induce the formation of the cleavable complex as 
from 25 µM. For the analogue 9b a lower poisoning effect emerges from 
the experiments reported in Figure 5. Indeed, for this latter derivative, a 
concentration of 500 µM has to be used to detect a significant increase in 
the band corresponding to the nicked DNA. For the well-known poison 
CPT, as expected, a notable amount of nicked DNA is formed already at 
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0.5 µM concentration. It is interestingly to note that these results are in 
agreement with cytotoxicity data reported in Table 3. Indeed, 13 
demonstrates an antiproliferative effect clearly higher with respect to 9b, 
with GI50 values from 4 to 11 times lower, depending on the cell line 
taken into consideration. As regard CPT, its cytotoxicity is notably higher 
with respect to both new derivatives and indeed GI50 even in the 
nanomolar range are obtained (Table 3). Thus, it can be concluded that a 
correlation can be drawn between the poisoning effect and the 
antiproliferative ability. 
4. Analysis of the binding mode 
 The binding mode of the most interesting compounds 13 and 9b was analyzed 
by docking calculations and compared to that of the reference crystallographic 
compound topotecan (Fig. 6). 
. 
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Fig. 6. Panel A: Predicted binding mode for compounds 13 (carbon atoms coloured in magenta) and 9b (carbon atoms coloured in orange). The 
crystallographic structure of topotecan (PDB code: 1K4T; carbon atoms coloured in green) is also reported as a reference. Panels B, C and D: 
diagram reporting all ligand interactions for topotecan and compounds 9b and 13, respectively. 
The docked conformation of reference compound topotecan is in excellent 
accord with the crystallographic structure (see Fig. S54, Supporting 
Information), providing support to the following discussion. Moreover, 
the binding energies computed for topotecan, 9b and 13 are -129.4, 128.2 
and -128.4 kcal/mol, respectively, thus the docking software correctly 
ranks the three compounds.  
The binding mode predicted for 9b and 13 (Fig.6, panels A, C and D) 
shows that the tetracyclic planar moiety is in both cases well packed in-
between the two DNA bases pairs made by deoxycytidine 599 and 
deoxyguanosine 576 (corresponding to the 5’ terminus of the cleaved 
DNA strand) and by deoxyadenosine 600 and thymidine 575, which is 
covalently bound to Tyr523 through its 3’ phosphate group. The 
benzonaphthyridinone group of 9b and 13 (rings A-C, Fig. 2) are partially 
overlaid with the pyrroloquinoline group of topotecan (rings A-C, Fig. 1 
and Fig. 6, panels A and B), with the scaffold of the former compounds 
being slightly shifted toward the α-helix formed by residues Thr518-
Tyr523. This shift allows compounds 9b and 13 to form a moderately 
strong H-bond involving the nitrogen atom of ring B and the guanidine 
group of Arg164 (N···H distance = 2.47 and 2.42 Å; N···H-N angle = 
169.0 and 170.8 deg. for compounds 9b and 13, respectively)[28].  
The charged pyrrole group (ring F, Fig. 2) of both 13 and 9b points 
toward the hydrophilic pocked made by Asp333 and Arg164 (Fig. 6, 
panels C and D). Moreover, is involved in a H-bond with nitrogen 3 of 
deoxyguanosine 576 (N···H distance = 2.15 and 2.22 Å; N ···H-N angle = 
140.1 and 142.2 deg. for compounds 9b and 13, respectively).  
The difference in antiproliferative activity (Table 3) and in topoisomerase 
I poisoning (Figs. 4 and 5) observed for compounds 9b and 13 are 
reasonably due to the substituent at C-3a. Indeed, the allyl chain of 9b is 
not apparently involved in any interaction with either topoisomerase or 
DNA. Conversely, a rather strong H-bond is observed between the 
hydroxyethyl substituent and the acidic group of Asp333 (H···O=C 
distance = 1.65 Å; O-H···O=C angle = 175.5 deg.). 
5. Conclusion 
We describes the preparation of a new scaffold starting from triptamines 
exploiting as a key step the sequential protocol Pd-catalyzed N-
arylation/intramolecular Friedel-Crafts alkylation. 
The antiproliferative activity of the derivatives due to the topoisomerase I 
inhibition has been evaluated. Although the potency of the new 
derivatives is two orders of magnitude lower than that of CPT, all 
compounds resulted active on at least two of the three evaluated cell lines. 
A computational binding mode analysis has thus been performed on 
compound 13 to provide insights possibly useful for designing decorations 
that might improve the activity of the scaffold here described. 
6. Experimental section 
6.1 Chemistry 
 
6.1.1 General remarks 
Melting points were determined on a Büchi B-540 heating apparatus and 
are uncorrected. 1H NMR and 13C NMR spectra were obtained on a 
VARIAN Gemini 200 M, VARIAN Oxford 300 MHz and XXX 500 MHz 
instruments. Chemical shifts are given in ppm downfield from SiMe4. 13C 
NMR spectra are 1H-decoupled and multiplicities were determined by the 
APT pulse sequence. Mass spectra were determined with a LCQ 
Advantage Thermo Finningan. Thin-layer chromatographic separations 
were performed on Merck silica-gel 60-F254 precoated. Preparative 
separations were performed by flash chromatography by using Merck 
silica gel 0.035-0.070 mm. 
6.1.2 Synthesis of methyl (2-(indol-3-yl)ethyl)carbamates 2. 
The products 2a[29] (yield 85%) and 2b[30]  (yield 91%) were synthesized 
following the procedure reported in literature[30]. 
6.1.3 Synthesis of tetrahydropyrrolindoles 3. 
To a solution of Pd(PPh3)4 (0.005 mmol) in THF (5 ml), cooled at 0 °C, 
was added the appropriate methyl (2-(indolin-3-yl)ethyl)carbamate 2 (1 
mmol), allyl alcohol (1.2 mmol), and Et3B (1M in THF, 1,2 mmol). The 
reaction mixture was stirred at rt for 24 h. Then the reaction mixture was 
poured into sat. NaHCO3, concentrated under vacuum and extracted with 
AcOEt (10 ml) for three time. The organic layer was dried over Na2SO4 
and concentrated under vacuum. The product was purified trough silica 
gel chromatography. 
Methyl 3a-allyl-3,3a,8,8a-tetrahydropyrrolo[2,3-b]indole-1(2H)-
carboxylate (3a). Yield: 77%. Eluent: Hexane/AcOEt 5:1. White solid. 
M.p.: 94-96 °C (Et2O/Hexane). 1H-NMR (300 MHz; C6D6) δ: 6.99 (m, 
1H); 6.83 (m, 1H); 6.73 (m, 1H); 6.33 (m, 1H); 5.59 (m, 1H); 5.22 (s, 
0.6H, exchange with D2O); 5.14 (s, 1H); 4.89 (m, 2H); 4.41 (s, 0.4H, 
exchange with D2O); 3.70 (t, J = 9.2 Hz, 0.3H); 3.49 (s, 1H); 3.45 (s, 2H); 
3.32 (t, J = 9.2 Hz, 0.7H); 2.92 (m, 1H); 2.16 (d, J = 6.9 Hz, 2H); 1.68 (m, 
1H); 1.55 (m, 1H) ppm. 13C-NMR (75 MHz; C6D6) δ: 154.3 (s); 154.2 (s); 
149.8 (s); 149.5 (s); 134.1 (s); 131.6 (s); 128.6 (d); 132.3 (d); 118.9 (d); 
118.6 (d); 117.9 (t); 117.8 (t); 109.5 (d); 109.2 (d); 80.6 (d); 79.7 (d); 57.5 
(s); 56.2 (t); 51.9 (q); 51.8 (q); 45.9 (t); 45.5 (t); 42.6 (t); 42.2 (t); 34.9 (t) 
ppm. m/z (ESI+): 259.2 [M+H]+, 258.1 [M+Na]+. IR (νmax/cm-1): = 3352; 
2949; 2890; 1686; 1608. Anal. calcd for C15H18N2O2: C, 69.74; H, 7.02; 
N, 10.84. Found: C, 69.70; H, 7.05; N, 10.87. 
Methyl 3a-allyl-5-methoxy-3,3a,8,8a-tetrahydropyrrolo[2,3-b]indole-
1(2H)-carboxylate (3b). Yield: 91%. Eluent: Hexane/AcOEt 2:1. White 
solid. M.p.: 65-67 °C (Et2O). 1H-NMR (200 MHz; CDCl3) δ: 6.58 (m, 
3H); 5.73 (m, 1H); 5.09 (m, 3H); 4.87 (bs, 1H, exchange with D2O); 3.74 
(s, 3H); 3.67 (s, 3H); 3.58 (m, 1H); 3.05 (m, 1H); 2.43 (d, J = 7.5 Hz, 2H); 
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2.13 (m, 2H) ppm. 13C-NMR (50 MHz; CDCl3) δ: 155.7 (s); 154.9 (s); 
153.9 (s); 153.7 (s); 143.4 (s); 143.1 (s); 133.8 (d); 133.5 (s); 133.4 (s); 
118.7 (t); 113.3 (d); 113.2 (d); 110.6 (d); 110.5 (d); 110.2 (d); 110.1 (d); 
81.8 (d); 80.5 (d); 58.1 (s); 57.0 (s); 56.2 (q); 52.7 (q); 52.4 (q); 46.0 (t); 
45.7 (t); 42.5 (t); 42.2 (t); 35.1 (t) ppm. m/z (ESI+): 289.1 [M+H]+. IR 
(νmax/cm-1): = 3350; 2949; 1693. Anal. calcd for C16H20N2O3: C, 66.65; H, 
6.99; N, 9.72. Found: C, 66.61; H, 7.03; N, 9.75. 
 
6.1.4 Synthesis of 2-chloroquinoline-3-dioxolanes 4. 
The products 4a[31] (yield 98%) and 4b[31] (yield 99%) were synthesized 
following the procedure reported in literature[31]. 
 
6.1.4 General procedure for N-arylation of tetrahydropyrrolindoles 3.  
To a solution of Pd2(dba)3 (0.02 mmol) and triisobutylphosphatrane (0.08 
mmol) in toluene (25 ml) were added 3 (1 mmol), the appropriate 2-
chloroquinoline 4 (1 mmol) and t-BuONa (1.4 mmol). The reaction 
mixture was warmed at 110 °C for 5 h. After completion the reaction 
mixture was filtered through a Celite pad, washed with brine (10 ml) for 
three time and extracted with AcOEt (15 ml). The organic layer was dried 
over Na2SO4 and concentrated under vacuum. The crude was purified 
trough silica gel chromatography. 
Methyl 8-(3-(1,3-dioxolan-2-yl)quinolin-2-yl)-3a-allyl-3,3a,8,8a-
tetrahydropyrrolo[2,3-b]indole-1(2H)-carboxylate (5a). Yield: 87%. 
Eluent: Hexane/AcOEt 1:1. White solid. M.p.: 127-130 °C 
(Et2O/Hexane). 1H-NMR (200 MHz; CDCl3) δ: 8.52 (s, 1H); 8.00 (d, J = 
8.4 Hz, 1H); 7.86 (d, J = 8.1 Hz, 1H); 7.68 (m, 1H); 7.51 (m, 1H); 7.11 
(m, 2H); 6.84 (m, 1H); 6.66 (m, 1H); 6.14 (s, 1H); 6.11 (s, 1H); 5.94 (m, 
1H); 5.15 (m, 2H); 4.22 (m, 2H); 3.97 (m, 2H); 3.33 (m, 2H); 2.85 (s, 
3H); 2.70 (m, 2H); 2.22 (m, 2H) ppm. 13C-NMR (50 MHz; CDCl3) δ: 
155.1 (s); 154.5 (s); 149.2 (s); 148.3 (s); 136.8 (d); 134.2 (d); 133.5 (s); 
130.2 (d); 129.7 (s); 128.9 (d); 128.6 (d); 128.0 (d); 127.2 (s); 126.5 (d); 
123.4 (d); 120.2 (d); 118.9 (t); 110.0 (d); 100.4 (d); 84.8 (d); 65.8 (t); 65.6 
(t); 57.6 (s); 51.9 (q); 45.8 (t); 43.4 (t); 36.1 (t) ppm. m/z (ESI+): 480.3 
[M+Na]+. IR (νmax/cm-1): = 3423 (br); 2950; 2855; 1706. Anal. calcd for 
C27H27N3O4: C, 70.88; H, 5.95; N, 9.18. Found: C, 70.84; H, 5.90; N, 
9.22. 
Methyl 8-(3-(1,3-dioxolan-2-yl)-6-methoxyquinolin-2-yl)-3a-allyl-
3,3a,8,8a-tetrahydropyrrolo[2,3-b]indole-1(2H)-carboxylate (5b). Yield: 
92%. Eluent: CH2Cl2/AcOEt 5:1. White solid. M.p.: 152-155 °C 
(Et2O/Hexane). 1H-NMR (200 MHz; CDCl3) δ: 8.41 (s, 1H); 7.89 (d, J = 
9.5 Hz, 1H); 7.33 (m, 1H); 7.14 (m, 1H); 7.05 (m, 2H); 6.81 (m, 1H); 6.55 
(m, 1H); 6.16 (s, 1H); 6.07 (s, 1H); 5.93 (m, 1H); 5.17 (m, 2H); 4.17 (m, 
2H); 4.03 (m, 2H); 3.92 (s, 3H); 3.31 (m, 2H); 2.90 (s, 3H); 2.69 (m, 2H); 
2.18 (m, 2H) ppm. 13C-NMR (50 MHz; CDCl3) δ: 158.0 (s); 155.2 (s); 
152.6 (s); 149.6 (s); 144.4 (s); 135.4 (d); 135.3 (d); 133.4 (s); 130.4 (d); 
130.0 (s); 128.6 (d); 128.2 (s); 123.3 (d); 122.9 (d); 120.0 (d); 118.8 (t); 
109.7 (d); 105.5 (d); 100.5 (d); 85.0 (d); 65.8 (t); 65.6 (t); 57.6 (s); 55.8 
(q): 51.9 (q); 45.8 (t); 43.5 (t); 36.3 (t) ppm. m/z (ESI+): 488.5 [M+H]+; 
510.3 [M+Na]+. IR (νmax/cm-1): = 3402 (br); 2951 (br); 1705. Anal. calcd 
for C28H29N3O5: C, 68.98; H, 6.00; N, 8.62. Found: C, 68.93; H, 5.97; N, 
8.66. 
Methyl 8-(3-(1,3-dioxolan-2-yl)quinolin-2-yl)-3a-allyl-5-methoxy-
3,3a,8,8a-tetrahydropyrrolo[2,3-b]indole-1(2H)-carboxylate (5c). Yield: 
92%. Eluent: CH2Cl2/ AcOEt 5:1. White solid. M.p.: 154-159 °C (Et2O/ 
Hexane). 1H-NMR (200 MHz; CDCl3) δ: 8.49 (s, 1H); 7.97 (d, J = 8.0 Hz, 
1H); 7.84 (d, J = 8.0 Hz, 1H); 7.66 (m, 1H); 7.48 (m, 1H); 6.69 (m, 3H); 
6.20 (s, 1H); 6.13 (s, 1H); 5.95 (m, 1H); 5.16 (m, 2H); 4.24 (m, 2H); 4.07 
(m, 2H); 3.75 (s, 3H); 3.31 (m, 2H,); 2.93 (s, 3H); 2.70 (m, 2H); 2.18 (m, 
2H) ppm. 13C-NMR (50 MHz; CDCl3) δ: 155.2 (s); 154.5 (s); 148.2 (s); 
143.3 (s); 136.8 (d); 135.2 (s); 134.9 (s); 134.2 (d); 130.2 (d); 129.5 (s); 
128.8 (t); 128.0 (d); 127.0 (s); 126.3 (d); 118.9 (s); 113.2 (d); 110.9 (d); 
110.4 (d): 100.5 (d); 85.3 (d); 65.8 (t); 65.6 (t); 57.8 (s); 56.2 (q); 51.9 (q); 
45.9 (t); 43.1 (t); 35.8 (t) ppm. m/z (ESI+): 488.4 [M+H]+; 510.3 [M+Na]+. 
IR (νmax/cm-1): = 3416 (br); 2950 (br); 1705. Anal. calcd for C28H29N3O5: 
C, 68.98; H, 6.00; N, 8.62. Found: C, 68.94; H, 5.98; N, 8.66. 
Methyl 8-(3-(1,3-dioxolan-2-yl)-6-methoxyquinolin-2-yl)-3a-allyl-5-
methoxy-3,3a,8,8a-tetrahydropyrrolo[2,3-b]indole-1(2H)-carboxylate 
(5d). Yield: 88%. Eluent: CH2Cl2/AcOEt 4:1. White solid. M.p.: 142-145 
°C (Et2O/Hexane). 1H-NMR (300 MHz; CDCl3) δ: 8.36 (s, 1H); 7.87 (d, J 
= 9.3 Hz, 1H); 7.32 (d, J = 9.3 Hz, 1H); 7.12 (d, J = 2.6 Hz, 1H); 6.74 (d, 
J = 1.8 Hz, 1H); 6.60 (m, 2H); 6.10 (s, 1H); 6.01 (s, 1H); 5.95 (m, 1H); 
5.18 (m, 2H); 4.20 (m, 2H); 4.04 (m, 2H); 3.91 (s, 3H); 3.74 (s, 3H); 3.30 
(m, 2H); 2.95 (s, 3H); 2.70 (m, 2H); 2.12 (m, 2H) ppm. 13C-NMR (75 
MHz; CDCl3) δ: 158.0 (s); 155.4 (s); 154.6 (s); 144.5 (s); 144.0 (s); 135.6 
(d); 135.3 (s); 134.4 (d); 130.5 (d); 130.0 (s); 128.2 (s); 123.0 (d); 119.0 
(t); 118.8 (s); 113.4 (d); 110.8 (d); 110.5 (d); 105.7 (d); 100.7 (d); 85.6 
(d); 66.0 (t); 65.8 (t); 57.9 (s); 56.4 (q); 56.0 (q); 52.1 (q); 46.0 (t); 43.4 
(t); 36.1 (t) ppm. m/z (ESI+): 518.2 [M+H]+; 540.2 [M+Na]+. IR (νmax/cm-
1): = 3393 (br); 2951 (br); 1705. Anal. calcd for C29H31N3O6: C, 67.30; H, 
6.04; N, 8.12. Found: C, 67.26; H, 6.00; N, 8.17. 
 
6.1.5 General procedure for the intramolecular Friedel-Crafts and 
oxidation reactions. 
a) To a solution of compound 5 (1 mmol) in CH2Cl2 (10 ml), cooled at 0 
°C, was added BF3-Et2O (3–5 mmol). The reaction mixture was stirred at 
rt for 48 h. After completion the mixture was poured into a sat. NaHCO3 
(25 ml) soln. at 0 °C, and stirred for 30 min. Then was extracted with 
CH2Cl2 (15 ml) for three time and the organic layer was dried under 
vacuum. b) The crude was dissolved in THF (40 ml) and water (10 ml), 
and MnO2 (3 mmol) and m-CPBA (0.05 mmol) were added. The reaction 
mixture was warmed at 60 °C for 12h. After the complete oxidation of the 
intermediate, the reaction mixture was filtered through a Celite pad and 
concentrated under vacuum. Then was extracted with AcOEt (15 ml) and 
washed with water (10 ml) for three time. The organic layer was dried 
over Na2SO4 and concentrated under vacuum. The crude was purified 
trough silica gel chromatography.  
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Methyl 3a-allyl-7-oxo-3,3a,7,14a-
tetrahydrobenzo[g]pyrrolo[2',3':2,3]indolo[1,7-ab][1,8]naphthyridine-
1(2H)-carboxylate (7a). Yield: 50%. Eluent: Hexane/AcOEt 7:1. Yellow 
solid. M.p.: 133-135 °C (Et2O/Hexane). 1H-NMR (200 MHz; CDCl3) δ: 
9.28 (d, 1H); 8.12 (d, J = 8.1 Hz, 1H); 7.96 (m, 2H); 7.72 (td, J = 6.8, 1.4 
Hz, 1H); 7.55 (dd, J = 7.1, 0.9 Hz, 1H), 7.44 (td, J = 7.1, 0.9 Hz, 1H); 
7.25 (m, 1H); 7.02 (s, 1H); 5.68 (m, 1H); 5.27 (m, 2H); 4.12 (m, 1H); 3.97 
(s, 3H); 2.84 (m, 3H); 2.12 (m, 2H) ppm.  13C-NMR (50 MHz; CDCl3) δ: 
179.7 (s); 155.4 (s); 150.0 (s); 147.9 (s); 145.8 (s); 139.5 (d); 135.5 (s); 
132.8 (d); 132.7 (d); 129.9 (d); 128.6 (d); 128.0 (d); 125.0 (d); 124.9 (d); 
124.7 (s); 122.7 (d): 120.2 (t); 119.2 (s); 117.7 (s); 81.9 (d); 58.2 (s); 53.2 
(q); 46.1 (t); 43.1 (t); 39.7 (t) ppm. m/z (ESI+): 434.2 [M+Na]+. IR 
(νmax/cm-1): = 3436 (br); 1698; 1655. Anal. calcd for C25H21N3O3: C, 
72.98; H, 5.14; N, 10.21. Found: C, 73.03; H, 5.09; N, 10.18. 
Methyl 3a-allyl-10-methoxy-7-oxo-3,3a,7,14a-
tetrahydrobenzo[g]pyrrolo[2',3':2,3]indolo[1,7-ab][1,8]naphthyridine-
1(2H)-carboxylate (7b). Yield: 62%. Eluent: CH2Cl2/AcOEt 6:1. Yellow 
solid. M.p.: 157-160 °C (Et2O/Hexane). 1H-NMR (200 MHz; CDCl3) δ: 
9.22 (s, 1H); 8.15 (dd, J = 8.1 ; 1.1 Hz, 1H); 7.90 (d, J = 9.5 Hz, 1H); 7.54 
(m, 2H); 7.24 (m, 2H); 7.01 (s, 1H); 5.70 (m, 1H); 5.09 (m, 2H); 4.14 (m, 
1H); 3.97 (s, 3H); 3.96 (s, 3H); 2.94 (m, 3H); 2.18 (m, 2H) ppm. 13C-
NMR (50 MHz; CDCl3) δ: 179.7 (s); 156.7 (s); 155.4 (s); 146.5 (s); 146.4 
(s); 145.8 (s); 137.6 (d); 135.2 (s); 132.8 (d); 129.5 (d); 128.3 (d); 126.4 
(d); 125.4 (s); 125.0 (d); 122.4 (d); 120.1 (t); 119.2 (s); 117.6 (s); 106.1 
(d); 81.9 (d); 58.2 (s); 55.8 (q); 53.1 (q); 46.1 (t); 43.1 (t); 39.7 (t) ppm. 
m/z (ESI-): 440.3 [M]-. IR (νmax/cm-1): = 3467 (br); 170; 1647. Anal. calcd 
for C26H23N3O4: C, 70.73; H, 5.25; N, 9.52. Found: C, 70.75; H, 5.24; N, 
9.49. 
Methyl 3a-allyl-5-methoxy-7-oxo-3,3a,7,14a-
tetrahydrobenzo[g]pyrrolo[2',3':2,3]indolo[1,7-ab][1,8]naphthyridine-
1(2H)-carboxylate (7c). Yield: 70%. Eluent: CH2Cl2/AcOEt 6:1. Orange 
solid. M.p.: 165-167 °C (Et2O/Hexane). 1H-NMR (200 MHz; CDCl3) δ: 
9.31 (s, 1H); 7.97 (m, 2H); 7.77 (m, 1H); 7.50 (d, J = 2.5 Hz, 1H); 7.44 
(m, 1H); 7.23 (d, J = 2.5 Hz, 1H); 7.02 (s, 1H); 5.71 (m, 1H); 5.18 (m, 
2H); 4.12 (m, 1H); 3.97 (s, 3H); 3.91 (s, 3H); 2.84 (m, 3H); 2.16 (m, 2H) 
ppm. 13C-NMR (50 MHz; CDCl3) δ: 179.3 (s);156.5 (s); 155.3 (s); 150.0 
(s); 147.4 (s); 140.9 (s); 139.5 (d); 137.1 (s); 132.6 (d, 2C); 132.6 (d); 
129.9 (d); 128.0 (d) 124.7 (d); 124.6 (s); 120.3 (t); 120.2 (d); 118.7 (s); 
117.5 (s); 103.8 (d); 82.1 (d); 58.1 (s); 56.3 (q); 53.2 (q); 46.0 (t); 43.0 (t); 
39.6 (t) ppm. m/z (ESI+): 464.3 [M+Na]+. IR (νmax/cm-1): = 3467 (br); 
1701; 1647. Anal. calcd for C26H23N3O4: C, 70.73; H, 5.25; N, 9.52. 
Found: C, 70.75; H, 5.30; N, 9.48. 
Methyl 3a-allyl-5,10-dimethoxy-7-oxo-3,3a,7,14a-
tetrahydrobenzo[g]pyrrolo[2',3':2,3]indolo[1,7-ab][1,8]naphthyridine-
1(2H)-carboxylate (7d). Yield: 80%. Eluent: Hexane/AcOEt 2:1. Orange 
solid. M.p.: 157-160 °C (Et2O/Hexane). 1H-NMR (200 MHz; CDCl3) δ: 
9.22 (s, 1H); 7.87 (d, J = 9.2 Hz, 1H); 7.48 (m, 2H); 7.24 (m, 2H); 7.00 
(m, 1H); 5.71 (m, 1H); 5.16 (m, 2H); 4.14 (m, 1H); 3.97 (s, 3H); 3.95 (s, 
3H); 3.92 (s, 3H); 2.83 (m, 3H); 2.36 (m, 2H) ppm. 13C-NMR (50 MHz; 
CDCl3) δ: 179.3 (s); 156.6 (s); 156.3 (s); 155.4 (s); 146.5 (s); 146.1 (s); 
140.9 (s); 137.5 (d); 137.2 (s); 132.7 (d); 129.5 (d); 126.5 (d); 125.3 (s); 
120.3 (t); 120.1 (d); 118.7 (s); 117.3 (s); 106.0 (d); 103.6 (d); 82.1 (d); 
58.1 (s); 56.3 (q); 56.8 (q); 53.2 (q); 46.0 (t); 43.0 (t); 39.6 (t) ppm. m/z 
(ESI+): 472.3 [M+H]+; 494.3 [M+Na]+. IR (νmax/cm-1): = 3437 (br); 2959 
(br); 1713; 1645. Anal. calcd for C27H25N3O5: C, 68.78; H, 5.34; N, 8.91. 
Found: C, 68.82; H, 5.35; N, 8.88. 
6.1.6 Synthesis of 3a-Allyl-5,10-dimethoxy-1-methyl-1,3,3a,14a-
tetrahydrobenzo[g]pyrrolo[2',3':2,3]indolo[1,7-ab][1,8]naphthyridin-
7(2H)-one (8).  
To a solution of compound 7d (1 mmol) in toluene (10 ml), cooled at 0 
°C, Red-Al® (65% in toluene, 10 mmol) was added dropwise. After 10 
min at rt, the reaction mixture was warmed at 110° C for 5 h. After 
completion the reaction mixture was poured into H2O at 0 °C, stirred at rt 
for 30 min. Then the mixture was filtered through a Celite pad with 
AcOEt (30 ml) and washed with water (15 ml) for three time. The organic 
layer was dried over Na2SO4 and concentrated under vacuum. The product 
was purified trough silica gel chromatography. 
3a-Allyl-5,10-dimethoxy-1-methyl-1,3,3a,14a-
tetrahydrobenzo[g]pyrrolo[2',3':2,3]indolo[1,7-ab][1,8]naphthyridin-
7(2H)-one (8). Yield: 50%. Eluent: CH2Cl2/AcOEt 1:1. Orange solid. 
M.p.: 173-175 °C (Et2O/Hexane). 1H-NMR (200 MHz; CDCl3) δ: 9.23 (s, 
1H); 7.91 (d, J = 9.1 Hz, 1H); 7.50 (m, 2H); 7.24 (m, 1H); 7.18 (d, J = 2.4 
Hz, 1H); 5.99 (s, 1H); 5.68 (m, 1H); 5.11 (m, 2H); 3.95 (s, 3H); 3.91 (s, 
3H); 2.91 (s, 3H); 2.82 (m, 2H); 2.66 (m, 2H); 2.34 (m, 1H); 2.18 (m, 1H) 
ppm. 13C-NMR (50 MHz; CDCl3) δ: 179.4 (s); 156.4 (s); 156.2 (s); 147.2 
(s); 146.3 (s); 141.2 (s); 139.1 (s); 137.5 (d); 133.3 (d); 129.1 (d); 126.4 
(d); 125.2 (s); 119.9 (d); 119.6 (t); 118.7 (s); 117.5 (s); 106.0 (d); 103.1 
(d); 89.5 (d); 58.6 (s); 56.3 (q); 55.8 (q); 54.7 (t); 43.5 (t); 40.9 (q); 37.7 
(t) ppm. m/z (ESI+): 429.3 [M+Na]+. IR (νmax/cm-1): = 3401 (br); 2785 
(br); 1640. Anal. calcd for C26H25N3O3: C, 73.05; H, 5.89; N, 9.83. Found: 
C, 73.01; H, 5.92; N, 9.80. 
 
6.1.7 General procedure for hydrolysis of methylcarbamate derivatives 7. 
To a solution of compound 7 (1 mmol) in EtOH (30 ml) was added NaOH 
(15 mmol) in H2O (5 ml). The reaction mixture was warmed at 80 °C until 
the consumption of the starting material (monitored by TLC). After 
completion the reaction mixture was concentrated under vacuum, 
extracted with AcOEt (25 ml) and washed with water (15 ml) for three 
time. The organic layer was dried over Na2SO4 and concentrated under 
vacuum. The product was purified trough silica gel chromatography. 
3a-Allyl-1,3,3a,14a-tetrahydrobenzo[g]pyrrolo[2',3':2,3]indolo[1,7-
ab][1,8]naphthyridin-7(2H)-one (9a). Yield: 66%. Eluent: Hexane/AcOEt 
1:2. Yellow solid. M.p.: 125-128 °C (Et2O/Hex). 1H-NMR (200 MHz; 
CDCl3) δ: 9.36 (s, 1H); 8.08 (dd, J = 8.1; 0.8 Hz, 1H); 7.98 (d, J = 9.1 Hz, 
2H); 7.77 (td, J = 7.0; 1.4 Hz, 1H); 7.57 (dd, J = 7.0; 0.8 Hz, 1H); 7.44 
(td, J = 8.1; 0.8 Hz, 1H); 7.21 (m, 1H); 6.20 (s, 1H); 5.80 (m, 1H); 5.17 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
LA REVUE GESTION ET ORGANISATION 00 (2013) 000–000                                                                                                                   12 
 
(m, 2H); 3.42 (bs, 1H, exchange with D2O); 3.16 (m, 1H); 2.80 (m, 3H); 
2.20 (m, 2H) ppm. 13C-NMR (50 MHz; CDCl3) δ: 179.7 (s); 150.0 (s); 
148.1  (s); 146.1 (s); 139.9 (d); 137.0 (s); 133.8 (d); 138.8 (d); 130.8 (d); 
128.6 (d); 127.6 (d); 124.6 (d); 124.5 (s); 124.4 (d); 122.6 (d); 119.4 (t); 
119.3 (s); 117.2 (s); 84.7 (d); 56.9 (s); 44.9 (t); 43.5 (t); 40.6 (t) ppm. m/z 
(ESI+): 354.2 [M+H]+; 376.1 [M+Na]+. IR (νmax/cm-1): = 3351 (br), 2930 
(br), 1651. Anal. calcd for C23H19N3O: C, 78.16; H, 5.42; N, 11.89. 
Found: C, 78.20; H, 5.45; N, 11.85. 
3a-Allyl-10-methoxy-1,3,3a,14a-
tetrahydrobenzo[g]pyrrolo[2',3':2,3]indolo[1,7-ab][1,8]naphthyridin-
7(2H)-one (9b). Yield: 85%. Eluent: Hexane/AcOEt 1:1. Yellow solid. 
M.p.: 94-96 °C (Et2O/Hexane). 1H-NMR (200 MHz; CDCl3) δ: 9.16 (s, 
1H); 8.07 (dd, J = 8.1; 1.1 Hz, 1H); 7.88 (d, J = 9.2 Hz, 1H); 7.53 (dd, J = 
7.0; 1.1 Hz, 1H); 7.43 (dd, J = 9.2; 2.6 Hz, 1H); 7.20 (m, 2H); 6.18 (s, 
1H); 5.76 (m, 1H); 5.13 (m, 2H); 3.92 (s, 3H); 3.27 (bs, 1H, exchange 
with D2O); 3.14 (m, 1H); 2.75 (m, 3H); 2.17 (m, 2H) ppm. 13C-NMR (50 
MHz; CDCl3) δ: 179.6 (s); 156.4 (s); 146.8 (s); 146.4 (s); 146.1 (s); 137.9 
(d); 137.0 (s); 133.9 (d); 129.0 (d); 128.4 (d); 126.4 (d); 125.2 (s); 124.3 
(d); 122.3 (d); 119.3 (t); 119.0 (s); 117.0 (s); 106.2 (d); 84.7 (d); 56.9 (s); 
55.8 (q); 44.9 (t); 43.5 (t); 40.6 (t) ppm. m/z (ESI+): 384.3 [M+H]+. IR 
(νmax/cm-1): = 3435 (br), 2932 (br), 1647. Anal. calcd for C24H21N3O2: C, 
75.18; H, 5.52; N, 10.96. Found: C, 75.22; H, 5.54; N, 10.93. 
3a-Allyl-5-methoxy-1,3,3a,14a-
tetrahydrobenzo[g]pyrrolo[2',3':2,3]indolo[1,7-ab][1,8]naphthyridin-
7(2H)-one (9c). Yield: 68%. Eluent: Hexane/AcOEt 1:2. Orange solid. 
M.p.: 165-168 °C (Et2O/Hexane). 1H-NMR (200 MHz; CDCl3) δ: 9.30 (s, 
1H); 7.97 (d, J = 8.8 Hz, 2H); 7.76 (td, J = 7.7; 0.7 Hz, 1H); 7.42 (m, 2H); 
7.23 (d, J = 2.3 Hz, 1H); 6.21 (s, 1H); 5.77 (m, 1H); 5.15 (m, 2H); 3.90 (s, 
3H); 3.43 (bs, 1H, exchange with D2O); 3.15 (m, 1H); 2.78 (m, 3H); 2.25 
(m, 1H); 2.10 (m, 1H) ppm. 13C-NMR (50 MHz; CDCl3) δ: 179.2 (s); 
156.5 (s); 150.0 (s);147.6 (s); 141.3 (s); 139.8 (d); 139.0 (s); 133.7 (d); 
132.7 (d); 130.1 (d); 127.6 (d) 124.4 (d); 124.3 (s); 120.4 (d); 119.5 (t); 
118.7 (s); 116.8 (s); 103.1 (d) 84.9 (d); 56.9 (s); 56.3 (q); 44.9 (t); 43.3 (t); 
40.5 (t) ppm. m/z (ESI+): 384.3 [M+H]+. IR (νmax/cm-1): = 3435 (br), 1932 
(br), 1645. Anal. calcd for C24H21N3O2: C, 75.18; H, 5.52; N, 10.96. 
Found: C, 75.21; H, 5.49; N, 10.94. 
3a-Allyl-5,10-dimethoxy-1,3,3a,14a-
tetrahydrobenzo[g]pyrrolo[2',3':2,3]indolo[1,7-ab][1,8]naphthyridin-
7(2H)-one (9d). Yield: 65%. Eluent: Hexane/AcOEt 1:2. Orange solid. 
M.p.: 165-168 °C (Et2O/Hexane). 1H-NMR (200 MHz; CDCl3) δ: 9.24 (s, 
1H); 7.92 (d, J = 9.1 Hz, 1H); 7.43 (m, 2H); 7.22 (m, 2H); 6.21 (s, 1H); 
5.75 (m, 1H); 5.16 (m, 2H); 3.96 (s, 3H); 3.92 (s, 3H); 3.43 (bs, 1H, 
exchange with D2O); 3.16 (m, 1H); 2.78 (m, 3H); 2.24 (m, 1H); 2.10 (m, 
1H) ppm. 13C-NMR (50 MHz; CDCl3) δ: 179.0 (s); 156.3 (s, 2C); 146.5 
(s); 146.3 (s); 141.3 (s); 139.0 (s); 137.8 (d); 133.7 (d); 129.0 (d); 126.4 
(d); 125.1 (s); 120.2 (d); 119.4 (t); 118.7 (s); 116.6 (s); 106.1 (d); 102.9 
(d) 84.9 (d); 56.9 (s); 56.2 (q); 55.8 (q); 44.9 (t); 43.3 (t) 40.5 (t) ppm. m/z 
(ESI+): 414.3 [M+H]+. IR (νmax/cm-1): = 3435 (br), 2933 (br), 1640. Anal. 
calcd for C25H23N3O3: C, 72.62; H, 5.61; N, 10.16. Found: C, 72.65; H, 
5.57; N, 10.12. 
 
6.1.8 General procedure for hydrolysis of methylether derivatives 9. 
To a solution of compound 9 (1 mmol) in CH2Cl2 (10 ml), cooled at -78 
°C, was added dropwise BBr3 (1M in Hexane, 2.5 mmol). After 1 h at rt 
the mixture was warmed at 40 °C until the consumption of the starting 
material (monitored by TLC). Then the mixture, cooled at 0 °C, was 
poured into a sat. NaHCO3 (25 ml) and was extracted with CH2Cl2 (15 ml) 
for three time. The organic layer was dried over Na2SO4 and concentrated 
under vacuum. The product was purified by crystallization 
(AcOEt/Hexane). 
3a-Allyl-10-hydroxy-1,3,3a,14a-
tetrahydrobenzo[g]pyrrolo[2',3':2,3]indolo[1,7-ab][1,8]naphthyridin-
7(2H)-one (10b). Yield: 70%. Red solid. M.p.: 296-299 °C 
(AcOEt/Hexane). 1H-NMR (200 MHz; DMSO) δ: 10.04 (s, 1H, exchange 
with D2O); 9.12 (s, 1H); 7.88 (m, 2H); 7.70 (d, J = 6.2 Hz, 1H); 7.45 (m, 
2H); 7.22 (m, 1H); 6.08 (s, 1H); 5.70 (m, 1H); 5.12 (d, J = 17.1 Hz, 1H); 
5.00 (dd, J = 10.1; 2.2 Hz, 1H); 4.20 (bs, 1H, exchange with D2O); 2.95 
(m, 1H); 2.65 (m, 3H); 2.10 (m, 2H) ppm. 13C-NMR (50 MHz; DMSO) δ:  
179.0 (s); 154.6 (s); 146.4 (s); 146.1 (s); 145.3 (s); 137.7 (s); 137.4 (d); 
135.0 (d); 129.4 (d); 129.0 (d); 126.9 (d); 125.8 (s); 123.8 (d); 122.7 (d); 
119.4 (s); 119.2 (t); 116.5 (s); 110.2 (d); 84.5 (d); 57.4 (s); 57.4 (t); 45.3 
(t); 43.1 (t) ppm. m/z (ESI+): 370.3 [M+H]+. IR (νmax/cm-1): = 3419 (br); 
2961 (br) ; 1643. Anal. calcd for C23H19N3O2: C, 74.78; H, 5.18; N, 11.37. 
Found: C, 74.74; H, 5.22; N, 11.40. 
3a-Allyl-5,10-dihydroxy-1,3,3a,14a-
tetrahydrobenzo[g]pyrrolo[2',3':2,3]indolo[1,7-ab][1,8]naphthyridin-
7(2H)-one (10d). Yield: 80%. Red solid. M.p.: 342-345 °C 
(AcOEt/Hexane). 1H-NMR (200 MHz; DMSO) δ: 10.02 (bs, 1H, 
exchange with D2O); 9.70 (bs, 1H,  exchange with D2O); 9.10 (s, 1H); 
7.85 (d, J = 9.2 Hz, 1H); 7,51-7.23 (m, 4H); 6.16 (s, 1H); 6.57 (bs, 1H, 
exchange with D2O); 5.66 (m, 1H); 5.08 (m, 2H); 3.14 (m, 1H); 2.73 (m, 
3H); 2.17 (m, 2H) ppm. 13C-NMR (50 MHz; DMSO) δ:  178.4 (s); 154.4 
(s); 154.3 (s); 145.7 (s); 145.2 (s); 139.7 (s); 138.4 (s); 137.3 (d); 134.6 
(d); 128.9 (d); 127.0 (d); 125.7 (s); 120.4 (d); 119.7 (s); 118.5 (t); 117.0 
(s); 110.2 (d); 106.4 (d); 83.3 (d); 57.7 (s); 57.7 (t); 45.5 (t); 42.7 (t) ppm. 
m/z (ESI+): 386.3 [M+H]+. IR (νmax/cm-1): = 3323 (br); 1623. Anal. calcd 
for C23H19N3O3: C, 71.67; H, 4.97; N, 10.90. Found: C, 71.65; H, 5.01; N, 
10.92. 
 
6.1.9 Synthesis of 10-methoxy-7-oxo-3a-(2-oxoethyl)-3,3a,7,14a-
tetrahydrobenzo[g]pyrrolo[2',3':2,3]indolo[1,7-ab][1,8]naphthyridine-
1(2H)-carboxylate (11). 
To a solution of compound 7b (1 mmol) in THF (15 ml) and H2O (3 ml) 
was added NaIO4 (3 mmol), lutidine (2 mmol) and OsO4 (4% in H2O, 0.05 
mmol). The reaction mixture was stirred at rt. After 24 h the reaction 
mixture was concentrated under vacuum and was extracted with AcOEt 
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(20 ml). The organic layer was washed with H2O (10 ml) for three time, 
dried Na2SO4 and concentrated under vacuum. The product was purified 
trough silica gel chromatography. 
Methyl 10-methoxy-7-oxo-3a-(2-oxoethyl)-3,3a,7,14a-
tetrahydrobenzo[g]pyrrolo[2',3':2,3]indolo[1,7-ab][1,8]naphthyridine-
1(2H)-carboxylate (11). Yield: 75%. Eluent: CH2Cl2/AcOEt 2:1. Orange 
solid. M.p.: 241-243 °C (CH2Cl2/Hexane). 1H-NMR (300 MHz; CDCl3) δ: 
9.77 (s, 1H); 9.16 (s, 1H); 8.12 (dd, J = 8.0, 1.1 Hz, 1H); 7.86 (d, J = 9.3 
Hz, 1H); 7.60 (dd, J = 7.1, 1.1 Hz, 1H); 7.46 (dd, J = 9.3, 2.8 Hz, 1H); 
7.22 (m, 2H); 7.12 (s, 1H); 4.16 (m, 1H); 3.96 (s, 3H); 3.94 (s, 3H); 3.27 
(ddd, J = 22.5, 18.1, 0.8 Hz, 2H); 2.95 (dt, J = 12.1, 5.5 Hz, 1H); 2.38 (m, 
1H); 2.22 (m, 1H) ppm. 13C-NMR (75 MHz; CDCl3) δ: 198.8 (d); 179.5 
(s); 156.7 (s); 155.4 (s); 146.3 (s); 145.6 (2C, s); 137.7 (d); 134.2 (s); 
129.4 (d); 128.7 (d); 126.5 (d); 125.5 (s); 125.4 (d); 122.6 (d); 119.1 (s); 
117.6 (s); 106.1 (d); 82.5 (d); 55.9 (q); 54.9 (s); 53.3 (q); 52.2 (t); 45.7 (t); 
40.2 (t) ppm. m/z (ESI+): 444.1 [M+H]+. IR (νmax/cm-1): = 3437 (br); 
2945; 1718; 1701. Anal. calcd for C25H21N3O5: C, 67.71; H, 4.77; N, 9.48. 
Found: C, 67.75; H, 4.73; N, 9.45. 
 
6.1.10 Synthesis of methyl 3a-(2-hydroxyethyl)-10-methoxy-7-oxo-
3,3a,7,14a-tetrahydrobenzo[g]pyrrolo[2',3':2,3]indolo[1,7-
ab][1,8]naphthyridine-1(2H)-carboxylate (12). 
To a solution of compound 11 (1 mmol) in MeOH (10 ml), cooled at 0 °C, 
was added NaBH4 (1.2 mmol) and the reaction mixture was stirred at rt. 
After 3 h the reaction mixture was poured into H2O (25 ml) and 
concentrated under vacuum. Then the mixture was extracted with AcOEt 
(15 ml) and washed with brine (10 ml) for three time. The organic layer 
was dried Na2SO4 and concentrated under vacuum. The product was 
purified trough silica gel chromatography. 
Methyl 3a-(2-hydroxyethyl)-10-methoxy-7-oxo-3,3a,7,14a-
tetrahydrobenzo[g]pyrrolo[2',3':2,3]indolo[1,7-ab][1,8]naphthyridine-
1(2H)-carboxylate (12). Yield: 65%. Yellow solid. Eluent: EtOAc. M.p.: 
121-123 °C (CH2Cl2/Hexane). 1H-NMR (300 MHz; CDCl3) δ: 8.95 (s, 
1H); 7.91 (d, J = 8.1 Hz, 1H); 7.73 (d, J = 9.3 Hz, 1H); 7.48 (d, J = 7.1 
Hz, 1H); 7.35 (dd, J = 9.3; 2.6 Hz, 1H); 7.21 (s, 1H); 7.17 (m, 1H); 7.10 
(d, J = 2.6 Hz, 1H); 4.05 (m, 1H); 3.94 (s, 3H); 3.91 (s, 3H); 3.72 (m, 2H); 
2.83 (m, 1H); 2.58 (br s, 1H, exchange with D2O); 2.34 (m, 2H); 2.17 (m, 
2H) ppm. 13C-NMR (75 MHz; CD l3) δ: 179.4 (s); 156.5 (s); 155.5 (s); 
146.2 (s, 2C); 145.8 (s); 137.4 (d); 134.6 (s); 129.1 (d); 128.3 (d); 126.4 
(d); 125.2 (s); 124.9 (d); 122.2 (d); 118.8 (s); 117.3 (s); 106.1 (d); 82.2 
(d); 59.7 (t); 57.0 (s); 55.8 (q); 53.1 (q); 45.5 (t); 41.0 (t); 40.7 (t) ppm. 
m/z (ESI+): 446.1 [M+H]+. IR (νmax/cm-1): = 3451; 2956; 1673; 1650; 
1626; 1606; 1598. Anal. calcd for C25H23N3O5: C, 67.41; H, 5.20; N, 9.43. 
Found: C, 67.45; H, 5.24; N, 9.40. 
 
6.1.11 Synthesis of 3a-(2-hydroxyethyl)-10-methoxy-1,3,3a,14a-
tetrahydrobenzo[g]pyrrolo[2',3':2,3]indolo[1,7-ab][1,8]naphthyridin-
7(2H)-one (13). 
To a solution of compound 12 (1 mmol) in EtOH (30 ml) was added 
NaOH (15 mmol) in H2O (5 ml). The reaction mixture was warmed at 80 
°C. After 6 h the reaction mixture was concentrated under vacuum, 
extracted with AcOEt (25 ml) and washed with H2O (15 ml) for three 
time. The organic layer was dried over Na2SO4 and concentrated under 
vacuum. The product was purified trough silica gel chromatography. 
3a-(2-Hydroxyethyl)-10-methoxy-1,3,3a,14a-
tetrahydrobenzo[g]pyrrolo[2',3':2,3]indolo[1,7-ab][1,8]naphthyridin-
7(2H)-one (13). Yield: 61%. Eluent: AcOEt/MeOH 20:1. Yellow solid. 
M.p.: 211-213 °C (CH2Cl2/Hexane). 1H-NMR (300 MHz; DMSO) δ: 9.21 
(s, 1H); 7.90 (m, 2H); 7.69 (d, J = 7.1 Hz, 1H); 7.64 (d, J = 2.8 Hz, 1H); 
7.54 (dd, J = 9.2; 2.8 Hz, 1H); 7.23 (m, 1H); 6.30 (s, 1H); 4.15 (t, J = 4.8 
Hz, 1H, exchange with D2O); 3.90 (s, 3H); 3.69 8 (br s, 1H, exchange 
with D2O); 3.38 (m, 2H); 2.95 (m, 1H); 2.44 (m, 1H); 2.27-1.97 (m, 4H) 
ppm. 13C-NMR (75 MHz; DMSO) δ: 178.9 (s); 156.3 (s); 146.9 (s); 146.3 
(s): 146.2 (s); 137.9 (d); 137.8 (s); 129.4 (d); 129.1 (d); 126.8 (d); 125.4 
(s); 123.5 (d); 122.8 (d); 119.3 (s); 116.6 (s); 107.6 (d); 85.3 (d); 58.6 (s); 
56.4 (t); 56.3 (q); 44.8 (t); 41.7 (t); 41.4 (t) ppm. m/z (ESI+): 388.1 
[M+H]+; 410.0 [M+Na]+. IR (νmax/cm-1): = 3434 (br); 2915; 2876; 1651. 
Anal. calcd for C23H21N3O3: C, 71.30; H, 5.46; N, 10.85. Found: C, 71.33; 
H, 5.49; N, 10.82. 
 
6.1.12 Synthesis of 10-hydroxy-3a-(2-hydroxyethyl)-7-oxo-1,2,3,3a,7,14a-
tetrahydrobenzo[g]pyrrolo[2',3':2,3]indolo[1,7-ab][1,8]naphthyridin-1-
ium bromide (14). 
To a solution of compound 13 (1 mmol) in CH2Cl2 (10 ml), cooled at -78 
°C, was added dropwise BBr3 (1M in Hexane, 2.5 mmol). After 1 h at rt 
the mixture was warmed at 40 °C for 12 h. Then the reaction mixture was 
poured over ice and the organic layer was separated, dried over Na2SO4 
and concentrated under vacuum. The crude product was used directly for 
the subsequent reaction without purification. 
10-Hydroxy-3a-(2-hydroxyethyl)-7-oxo-1,2,3,3a,7,14a-
tetrahydrobenzo[g]pyrrolo[2',3':2,3]indolo[1,7-ab][1,8]naphthyridin-1-
ium bromide (14). Yield: 50%. Red solid. 255-256 °C (CH2Cl2/AcOEt).  
1H-NMR (300 MHz; DMSO) δ: 10.47 (br s, 1H, exchange with D2O); 
9.57 (br s, 1H, exchange with D2O); 9.16 (s, 1H); 8.00-7.83 (m, 3H); 7.60 
(m, 1H); 7.48 (d, J = 2.7 Hz, 1H); 7.36 (m, 1H); 6.68 (s, 1H); 4.70 (br s, 
2H, exchange with D2O); 3.46 (m, 2H); 3.11 (m, 1H); 2.88 (m, 1H); 2.47 
(m, 2H); 2.24 (m, 2H) ppm. 13C-NMR (75 MHz; DMSO) δ: 170.1 (s); 
155.1 (s); 145.7 (s); 144.7 (s); 137.8 (d); 134.6 (s); 130.0 (d); 129.0 (d); 
127.3 (d); 126.5 (s); 126.2 (s); 124.8 (d); 123.8 (d); 119.2 (s); 117.7 (s); 
110.6 (d); 80.2 (d); 57.9 (t); 57.7 (s); 57.6 (t); 45.0 (t); 37.9 (t) ppm. m/z 
(ESI+): 374.3; (ESI-): 372.3. IR (νmax/cm-1): = 3435; 2929; 2709; 1670; 
1641; 1640.  
 
6.1.13 General procedure for synthesis of t-butylcarbamates 15. 
To a solution of compound 10b or 14 (1 mmol) in EtOH (10 ml) was 
added TEA (3 mmol) and (Boc)2O (3 mmol). The reaction mixture was 
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stirred at rt for 48 h. After consumption of starting material (monitored by 
TLC) the mixture was concentrated under vacuum and extracted with 
AcOEt (15 ml). The organic layer was washed with H2O (10 ml) for three 
time, dried over Na2SO4 and concentrated under vacuum. The crude, 
consisting of a mixture of mono- and di-protected product, was diluted in 
EtOH (10 ml) and piperidine (3 mmol) was added, in order to remove the 
Boc on the OH in position 10. The reaction mixture was stirred at 80 °C 
until the consumption of the di-protected intermediate (monitored by 
TLC). Then the mixture was poured in H2O (25 ml) and was extracted 
with CH2Cl2 (15 ml) for three time. The organic layer was dried over 
Na2SO4 and concentrated under vacuum. The product was purified trough 
silica gel chromatography. 
tert-Butyl 3a-allyl-10-hydroxy-7-oxo-3,3a,7,14a-
tetrahydrobenzo[g]pyrrolo[2',3':2,3]indolo[1,7-ab][1,8]naphthyridine-
1(2H)-carboxylate (15a). Yield: 60%. Eluent: Hexane/AcOEt 1:1. Orange 
solid. M.p.: 147-149 °C (CH2Cl2/Hexane). 1H-NMR (300 MHz; DMSO) 
δ: 10.15 (s, 1H, exchange with D2O); 9.06 (s, 1H); 7.91 (d. J = 8.1 Hz, 
1H); 7.76 (m, 2H); 7.50 (dd, J = 9.1; 2.6 Hz, 1H); 7.39 (d, J = 2.6 Hz, 
1H); 7.25 (m, 1H); 6.88 (s, 1H); 5.67 (m, 1H); 5.18 (d, J = 17.1 Hz, 1H); 
5.07 (d, J = 9.9 Hz, 1H); 3.89 (m, 1H); 2.72 (m, 3H); 2.09 (m, 2H); 1.53 
(s, 9H) ppm. 13C-NMR (75 MHz; DMSO) δ: 179.1 (s); 157.7 (s); 153.7 
(s); 146.1 (s); 145.9 (s); 145.2 (s); 137.1 (d); 135.5 (s); 134.3 (d); 129.3 
(d); 128.9 (d); 126.9 (d); 125.9 (t); 124.2 (d); 122.9 (d); 120.1 (s); 119.2 
(s); 117.0 (s); 110.2 (d); 82.0 (d); 80.2 (s); 57.8 (s); 46.1 (t); 42.4 (t); 40.0 
(t); 28.9 (q, 3C) ppm. m/z (ESI+): 470.0 [M+H]+; 492.0 [M+Na]+. IR 
(νmax/cm-1): = 3403; 2976; 2930; 1700; 1623; 1606; 1587. Anal. Calcd for 
C28H27N3O4: C, 71.62; H, 5.80; N, 8.95. Found: C, 71.58; H, 5.78; N, 
8.99. 
tert-Butyl 10-hydroxy-3a-(2-hydroxyethyl)-7-oxo-3,3a,7,14a-
tetrahydrobenzo[g]pyrrolo[2',3':2,3]indolo[1,7-ab][1,8]naphthyridine-
1(2H)-carboxylate (15b). Yield: 80%. Eluent: Hexane/AcOEt: 1:4. M.p.: 
207-209 °C dec. (CH2Cl2/Hexane). 1H-NMR (300 MHz; C3D6O) δ: 9.06 
(s, 1H); 8.96 (s, 1H, exchange with D2O); 8.00 (dd, J = 8.1; 1.1 Hz, 1H); 
7.98 (d, J = 9.2 Hz, 1H); 7.72 (dd, J = 7.1; 1.1 Hz, 1H); 7.56 (dd, J = 9.2; 
2.7 Hz, 1H); 7.44 (d, J = 2.7 Hz, 1H); 7.32 (s, 1H); 7.27 (dd, J = 8.1; 7.1 
Hz, 1H); 4.06 (m, 1H); 3.71-3.53 (m, 3H, 2H after exchange with D2O); 
2.80 (m, 1H); 2.42-2.14 (m, 4H); 1.62 (s, 9H). 13C-NMR (75 MHz; 
C3D6O) δ: 178.8 (s); 154.3 (s); 154.2 (s); 146.4 (s); 146.3 (s); 145.6 (s); 
136.4 (d); 135.8 (s); 129.3 (d); 128.7 (d); 125.8 (d); 125.7 (s); 123.9 (d); 
122.1 (d); 119.3 (s); 117.2 (s); 109.6 (d); 82.7 (d); 79.6 (s); 58.7 (t); 58.6 
(s); 45.2 (t); 41.4 (t); 40.1 (t); 28.1 (q, 3C). m/z (ESI+): 474.2 [M+H]+. IR 
(νmax/cm-1): 3414; 2959; 2927; 1702; 1638; 1622; 1608; 1586. Anal. Calcd 
for C27H27N3O5: C, 68.48; H, 5.75; N, 8.87. Found: C, 68.44; H, 5.72; N, 
8.91. 
 
6.1.14 General procedure for Mannich reaction. 
To a solution of compound 15 (1 mmol) in EtOH (25 ml) was added 
CH2O (37% in H2O, 4 mmol) and Me2NH (40% in H2O, 3 mmol). The 
reaction mixture was stirred at rt for 24-48 h. After consumption of 
starting material (monitored by TLC) the mixture was concentrated under 
vacuum and H2O (25ml) was added. The mixture was extracted with 
CH2Cl2 (15 ml) for three time. The organic layer was dried over Na2SO4 
and concentrated under vacuum. The product was purified trough silica 
gel chromatography. 
tert-Butyl 3a-allyl-9-((dimethylamino)methyl)-10-hydroxy-7-oxo-
3,3a,7,14a-tetrahydrobenzo[g]pyrrolo[2',3':2,3]indolo[1,7-
ab][1,8]naphthyridine-1(2H)-carboxylate (16a). Yield: 56%. Eluent: 
AcOEt/MeOH 20:1. Orange solid. M.p.: 125-127 °C dec. 
(CH2Cl2/Hexane). 1H-NMR (300 MHz; CDCl3) δ: 9.34 (s, 1H); 8.16 (dd, J 
= 8.1; 1.0 Hz, 1H); 7.97 (d, J = 9.1 Hz, 1H); 7.57 (dd, J = 7.1; 1.0 Hz, 
1H); 7.47 (d, J = 9.1 Hz, 1H); 7.26 (dd, J = 8.1; 7.1 Hz, 1H); 7.08 (s, 1H);  
5.78 (m, 1H); 5.23 (dd, J = 8.5; 1.4 Hz, 1H); 5.15 (d, J = 10.5 Hz, 1H); 
4.28 (s, 2H), 4.10 (m, 1H); 2.88 (m, 2H); 2.73 (m, 2H); 2.50 (s, 6H); 2.18 
(m, 2H); 1.64 (s, 9H) ppm. 13C-NMR (75 MHz; CDCl3) δ: 179.8 (s); 155.5 
(s); 153.6 (s); 146.0 (s); 145.7 (s); 145.4 (s); 135.4 (s); 132.8 (d); 131.7 
(d); 129.1 (d); 128.1 (d); 126.7 (d); 124.6 (d); 123.8 (s); 122.0 (d); 119.9 
(t); 118.3 (s); 117.1 (s); 111.9 (s); 81.9 (d); 80.5 (s); 57.5 (t); 57.5 (s); 45.8 
(t); 45.6 (q, 2C); 42.9 (t); 39.9 (t); 28.5 (q, 3C) ppm.  m/z (ESI+): 527.0 
[M+H]+; 550.0 [M+Na]+. IR (νmax/cm-1): 3436; 3061; 2976; 2784; 1704; 
1644; 1618; 1606; 1586. Anal. Calcd for C31H34N4O4: C, 70.70; H, 6.51; 
N, 10.64. Found: C, 70.68; H, 6.48; N, 10.67. 
tert-Butyl 9-((dimethylamino)methyl)-10-hydroxy-3a-(2-hydroxyethyl)-7-
oxo-3,3a,7,14a-tetrahydrobenzo[g]pyrrolo[2',3':2,3]indolo[1,7-
ab][1,8]naphthyridine-1(2H)-carboxylate (16b). Yield: 60%. Eluent: 
AcOEt/MeOH 19:1. Orange solid. M.p.: 157-159 °C dec. 
(AcOEt/Hexane). 1H-NMR (300 MHz; CDCl3) δ: 9.11 (s, 1H); 7.86 (d, J 
= 7.7 Hz, 1H); 7.63 (d, J = 9.1 Hz, 1H); 7.41 (d, J = 6.9 Hz, 1H); 7.22 (d, 
J = 9.1 Hz, 1H); 7.16 (s, 1H); 7.10 (m, 1H); 6.50 (br s, 1H, exchange with 
D2O); 4.40 (d, J = 14.7 Hz, 1H); 4.22 (d, J = 14.7 Hz, 1H); 3.90 (m, 1H); 
3.75 (br s, 2H); 2.68 (m, 1H); 2.48 (s, 6H); 2.38 (m, 3H, 2H after 
exchange with D2O); 2.09 (m, 2H); 1.51 (s, 9H) ppm. 13C-NMR (75 MHz; 
CDCl3) δ: 179.5 (s); 155.5 (s); 153.9 (s); 145.8 (s); 145.6 (s); 144.9 (s); 
134.9 (s); 131.8 (d); 128.6 (d); 128.0 (d); 126.7 (d); 124.5 (d); 123.7 (s); 
121.9 (d); 118.0 (s); 116.8 (s); 112.3 (s); 82.0 (d); 80.8 (s); 59.7 (t); 57.9 
(s); 56.4 (t); 45.6 (t); 44.9 (q, 2C); 41.4 (t); 40.6 (t); 28.7 (q; 3C) ppm.  
m/z (ESI+): 531.8 [M+H]+. IR (νmax/cm-1): 3435; 2974; 2954; 2928; 2882; 
1698; 1645; 1619; 1606; 1584. Anal. Calcd for C30H34N4O5: C, 67.91; H, 
6.46; N, 10.56. Found: C, 67.88; H, 6.43; N, 10.56. 
6.1.15 Synthesis of 3a-allyl-9-((dimethylamino)methyl)-10-hydroxy-
1,3,3a,14a-tetrahydrobenzo[g]pyrrolo[2',3':2,3]indolo[1,7-
ab][1,8]naphthyridin-7(2H)-one (17).  
To a solution of compund 16a (1 mmol) in MeOH (20 ml) was added 
TMSCl (5 mmol). The reaction mixture was stirred at rt for 6 h. After 
completion the mixture was poured into a sat. NaHCO3 (25 ml) and was 
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extracted with CH2Cl2 (15 ml) for three time. The organic layer was dried 
over Na2SO4 and was concentrated under vacuum. The product was 
purified trough silica gel chromatography. 
3a-Allyl-9-((dimethylamino)methyl)-10-hydroxy-1,3,3a,14a-
tetrahydrobenzo[g]pyrrolo[2',3':2,3]indolo[1,7-ab][1,8]naphthyridin-
7(2H)-one (17). Yield: 78%. Eluent: AcOEt/MeOH 19:1. Orange solid. 
M.p.: 285-287 °C dec. (CH2Cl2/Hexane). 1H-NMR (300 MHz; DMSO) δ: 
9.30 (s, 1H); 7.88 (d, J = 7.1 Hz, 1H); 7.79 (d, J = 9.1 Hz, 1H); 7.70 (d, J 
= 7.1 Hz, 1H); 7.47 (d, J = 9.1 Hz, 1H); 7.20 (m, 1H), 6.07 (s, 1H); 5.70 
(ddd, J = 17.0; 10.1; 2.0 Hz, 1H); 5.12 (d, J = 17.0, 1H); 5.00 (dd, J = 
10.1; 2.0 Hz. 1H); 4.04 (s, 2H); 2.97 (m, 1H); 2.80 (m, 1H); 2.65 (m, 1H); 
2.50 (m, 1H); 2.29 (s, 6H); 2.05 (m, 2H) ppm.  13C-NMR (75 MHz; 
DMSO) δ: 178.9 (s); 154.1 (s); 146.1 (s); 145.9 (s); 145.6 (s); 173.8 (s); 
135.0 (d); 134.0 (d); 129.3 (d); 128.4 (d); 126.6 (d); 124.6 (s); 123.8 (d); 
122.7 (d); 119.3 (t); 118.5 (s); 116.5 (s); 115.4 (s); 84.6 (d); 58.5 (s); 57.3 
(t); 55.4 (t); 45.3 (t); 45.1 (q, 2c); 43.1 (t) ppm.  m/z (ESI+): 427.0 
[M+H]+. IR (νmax/cm-1): 3435; 3067; 2919; 2850; 1648; 1618; 1605; 1586. 
Anal. Calcd for C26H26N4O2: C, 73.22; H, 6.14; N, 13.14. Found: C, 73.26; 
H, 6.18; N, 13.11. 
 
6.2 Biological evaluation. 
 
6.2.1 Inhibition Growth Assay.  
HeLa (human cervix adenocarcinoma cells) were grown in Nutrient 
Mixture F-12 [HAM] (Sigma Chemical Co.); H-460 (large cell lung 
carcinoma) and MSTO-211H (human biphasic mesothelioma cells) were 
grown in RPMI 1640 (Sigma Chemical Co.) supplemented with 2.38 g/L 
Hepes, 0.11 g/L pyruvate sodium and 2.5 g/L glucose. 1.5g/L NaHCO3, 
10% heat-inactivated fetal calf serum (Invitrogen), 100 U/mL penicillin, 
100 µg/mL streptomycin, and 0.25 µg/mL amphotericin B (Sigma 
Chemical Co.) were added to the media.  
The cells were cultured at 37°C in a moist atmosphere of 5% carbon 
dioxide in air. Cells (3-4 x 104) were seeded into each well of a 24-well 
cell culture plate. After incubation for 24 h, various concentrations of the 
test agents were added to the complete medium and incubated for a further 
72 h. A Trypan blue assay was performed to determine cell viability. 
Cytotoxicity data were expressed as GI50 values, i.e., the concentration of 
the test agent inducing 50% reduction in cell number compared with 
control cultures. 
 
6.2.2 Linear flow dichroism. 
Linear dichroism (LD) measurements were performed on a Jasco J500A 
circular dichroism spectropolarimeter, converted for LD and equipped 
with an IBM PC and a Jasco J interface. Linear dichroism was defined as: 
LD(λ) = A//(λ) - A⊥(λ) 
where A//  and A⊥ correspond to the absorbances of the sample when 
polarized light was oriented parallel or perpendicular to the flow direction, 
respectively. The orientation was produced by a device designed by Wada 
and Kozawa6 at a shear gradient of 500-700 rpm, and each spectrum was 
accumulated twice. 
Aqueous solutions of DNA (1.9 x 10-3M) in 10 mM TRIS, 1 mM EDTA 
(pH 7.0) and 0.01 M NaCl were used (ETN buffer). Spectra were recorded 
at 25°C at [drug]/[DNA]=0 and 0.08. 
 
6.2.3 Topoisomerase I-mediated DNA relaxation. 
Supercoiled pBR322 plasmid DNA (0.25 µg, Fermentas Life Sciences) 
was incubated with 2U topoisomerase I (human recombinant 
topoisomerase I, TopoGen) and the test compounds as indicated, for 60 
min at 37 °C in 20 µL reaction buffer. 
Reactions were stopped by adding 4 µL stop buffer (5% sodium dodecyl 
sulfate (SDS), 0.125% bromophenol blue, and 25% glycerol), 50 µg/mL 
proteinase K (Sigma) and incubating for a further 30 min at 37 °C. The 
samples were separated by electrophoresis on a 1% agarose gel at room 
temperature. The gels were stained with ethidium bromide 1 µg/mL in 
TAE buffer (0.04 M Tris-acetate and 0.001 M EDTA), transilluminated 
by UV light, and fluorescence emission was visualized by a CCD camera 
coupled to a Bio-Rad Gel Doc XR apparatus. 
 
6.2.4 Topoisomerase I-mediated DNA cleavage. 
Reaction mixtures (20 µL) containing 35 mM Tris-HCl (pH = 8.0), 72 
mM KCl, 5 mM MgCl2, 5 mM DTT, 5 mM spermidine, 0.01% bovine 
serum albumin, 20 ng pBR322 plasmid DNA (Fer- mentas Life Sciences), 
5 U topoisomerase I (human recombinant topoisomerase I, TopoGen) and 
test compounds at indicated concentrations were incubated for 60 min at 
37 oC. Reactions were stopped by adding 4 µL of stop buffer (5% SDS, 
0.125% bromophenol blue and 25% glycerol), 50 µg/ mL proteinase K 
(Sigma) and incubating for a further 30 min at 37 oC. The samples were 
separated by electrophoresis on a 1% agarose gel containing ethidium 
bromide 0.5 µg/mL (Sigma) at room temperature in TBE buffer (0.09 M 
Tris-borate and 0.002 M EDTA), transilluminated by UV light, and 
fluorescence emission was visualized by a CCD camera coupled to a Bio-
Rad Gel Doc XR apparatus. 
 
6.3 Computational analysis.  
The structure of the receptor was obtained from the crystal structure of the 
topoisomeraseI-DNA-topotecan ternary complex (PDB code: 1K4T) and 
prepared as previously described[32]. Docking calculations were performed 
with the software PLANTS[33]. The search space was defined by using the 
crystallographic ligand center of mass coordinates as the binding site 
center (x = 49.3764, y = 46.9081 and z = 48.2818) and the binding site 
radius was set to 14 Å, corresponding to the ligand radius of gyration 
augmented by 6 Å. Maximum accuracy was requested by setting the 
search_speed parameters to “speed1”. All the other parameters were used 
as default. Ligands were prepared using MOE 2015[34], and processed by 
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SPORES in order to assign the correct atom types required for docking 
calculations with PLANTS[35]. By using this setup, the overlay between 
the lowest energy docked conformation of topotecan (binding energy = -
129.4 kcal/mol, computed with the CHEMPLP scoring function)[36] and its 
crystallographic structure was excellent, with a RMSD of 1.52 Å, 
computed with VMD 1.9.1[37]. 
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- Design and synthesis of a new scaffold of Topo I inhibitors  
- The sequential Pd-catalyzed N-arylation/acylation reaction was the key step for the synthesis 
- The new compounds were evaluated for their antiproliferative activity against three cancer cell 
lines such as H-460, HeLa and MSTO-211H 
- Compound 13 exhibited the most potent inhibitory activity 
- Computational binding mode analysis has  been performed on the most active compounds  
